- Our Doctors
- Dr Rashmi Jadon
Dr Rashmi Jadon
MBBS, MRCP, FRCR, MD Consultant Clinical Oncologist
Specialises in
Radiotherapy and chemotherapy for rectal and anal cancer
Overview
Centers
Specialises in
Treatment
Dr Rashmi Jadon is a Consultant Clinical Oncologist at Addenbrooke’s Hospital, specialising in the oncological management of rectal cancer and anal cancer. Dr Jadon has expertise in both radiotherapy and chemotherapy for these cancers.
Having grown up in the north-east of England, Dr Jadon qualified as a doctor from Newcastle University in 2004. Dr Jadon completed her clinical oncology training in Leeds, Bristol, Bath, Ipswich and Norwich (2009 – 2017).
Dr Jadon undertook a 2-year research fellowship at Velindre Cancer Centre in Cardiff, specifically studying advanced radiotherapy techniques for patients with pelvic cancers. This led to her completing a research MD (Doctor of Medicine) from Cardiff University in 2017. Her research focussed on the use of advanced radiotherapy techniques in the pelvis to reduce short and long term side-effects for patients.
As a consultant at Addenbrooke’s Hospital since 2017, Dr Jadon is the lead consultant for rectal and anal cancers, continues to have a strong interest in research and contributes to several clinical trials of novel treatment approaches.
.svg){kind=icon}
Career positions
- Consultant in Clinical Oncology at Addenbrooke’s Hospital, Cambridge
Clinical interests
Dr Jadon has a long-standing interest in advanced radiotherapy techniques and using these techniques to improve the chance of cure for patients, whilst minimising the side-effects that a patient experiences. In particular she is interested in the long-term effects of treatments on patients and how these can be improved.
Dr Jadon is interested in improving cancer outcomes for patients with rectal and anal cancers, and ensures her practice is up-to-date according to research within her field.
Principles of her oncology practice are to:
- Listen carefully to her patients, understanding their needs as individuals.
- Have open and frank conversations with her patients regarding treatment options, and to make decisions in partnership with them.
- Educate and empower her patients to manage side effects that may occur with cancer treatments.
- To use up to date and evidenced-based treatments for her patients.
Research interests
- Advanced radiotherapy techniques for rectal and anal cancers
- Long term side effects of pelvic radiotherapy treatments and how to prevent them
- Clinical trials of novel treatment approaches for rectal and anal cancers
Professional memberships
- Fellow of the Royal College of Radiologists
- General Medical Council
- Medical Defence Union
Publications & affiliations
- Theophanous S, Lønne PI, Choudhury A, Berbee M, Dekker A, Dennis K, Dewdney A, Gambacorta MA, Gilbert A, Guren MG, Holloway L, Jadon R, Kochhar R. Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study. Diagnostic Prognostic Research. 2022 Aug 4;6(1):14. doi: 10.1186/s41512-022-00128-8. PMID: 35922837; PMCID: PMC9351222.
- Gatfield R, Hughes J, Kumaran M, Doherty G, Daly M, Stancliffe M, JephcottC, Wilson C, Smith S, Jadon R. Outcomes using induction chemotherapy followed by long-course chemoradiotherapy as total neoadjuvant therapy for locally advanced rectal cancer. Annals of Oncology June 2022 33:S329; 10.1016/j.annonc.2022.04.316
- Jadon R, Hanna L, Parsons P, Staffurth J. Dose-Volume Predictors for Patient-reported Late Diarrhoea, Faecal Incontinence and Urgency after Pelvic Radiotherapy. Clinical Oncology (R Coll Radiol). 2021 Aug;33(8):536-545. doi: 10.1016/j.clon.2021.03.011. Epub 2021 Apr 17. PMID: 33875359.
- Shor D, Jadon R, Jephcott C, Wilson CB. Chemoradiotherapy outcomes using intensity-modulated radiotherapy for anal squamous cell carcinoma: a single centre experience. Clinical Oncology December 2020 32: e1 10.1016/j.clon.2020.11.017
- Jadon R, Higgins E, Hanna L, Evans M, Coles B, Staffurth J. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology. 2019 Apr 3;14(1):57. doi: 10.1186/s13014-019-1262-8. PMID: 30943992; PMCID: PMC6448293.